Skip to main content
All lobbying filings

AKEBIA THERAPEUTICS, INC.

Lobbying for AKEBIA THERAPEUTICS, INC.

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $460,000.00 expenses · posted Jul 21, 2025

Official filing document

 Bills named in this filing 3
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 2199
    Restore Protections for Dialysis Patients Act
  • S 1173
    Restore Protections for Dialysis Patients Act
 Lobbying activity 2
Health Issues

H.R. 1, One Big Beautiful Bill Act, provisions related to health care H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.

Medicare/Medicaid

Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Implementation of the final CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem